You just read:

Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor

News provided by

Theravance Biopharma, Inc.

Nov 27, 2018, 07:55 ET